{"protocolSection":{"identificationModule":{"nctId":"NCT05170204","orgStudyIdInfo":{"id":"BO42777"},"secondaryIdInfos":[{"id":"2023-503920-14-00","type":"CTIS"}],"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer","acronym":"HORIZON 1"},"statusModule":{"statusVerifiedDate":"2025-07","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-11-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2032-08-21","type":"ESTIMATED"},"completionDateStruct":{"date":"2033-09-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-12-22","studyFirstSubmitQcDate":"2021-12-22","studyFirstPostDateStruct":{"date":"2021-12-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-07-03","lastUpdatePostDateStruct":{"date":"2025-07-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":71,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort A1: ALK-Positive (alectinib arm)","type":"EXPERIMENTAL","description":"Participants will receive alectinib 600 mg orally twice daily until completion of treatment period (3 years), or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first","interventionNames":["Drug: Alectinib"]},{"label":"Cohort A1: ALK-positive (durvalumab arm)","type":"ACTIVE_COMPARATOR","description":"Participants will receive 1500 mg of intravenous (IV) durvalumab every 4 weeks until completion of treatment period (1 year) or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first","interventionNames":["Drug: Durvalumab"]},{"label":"Cohort A2: ROS 1-positive (entrectinib arm)","type":"EXPERIMENTAL","description":"Participants will receive entrectinib 600 mg orally once daily until completion of treatment period (3 years), or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first.\n\nCohort A2 has been closed to enrollment.","interventionNames":["Drug: Entrectinib"]},{"label":"Cohort A2: ROS 1-positive (durvalumab arm)","type":"ACTIVE_COMPARATOR","description":"Participants will receive 1500 mg of IV durvalumab every 4 weeks until completion of treatment period (1 year) or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first\n\nCohort A2 has been closed to enrollment.","interventionNames":["Drug: Durvalumab"]}],"interventions":[{"type":"DRUG","name":"Alectinib","description":"Participants will receive oral alectinib twice daily with food.","armGroupLabels":["Cohort A1: ALK-Positive (alectinib arm)"]},{"type":"DRUG","name":"Entrectinib","description":"Participants will receive oral entrectinib once daily, with or without food.","armGroupLabels":["Cohort A2: ROS 1-positive (entrectinib arm)"]},{"type":"DRUG","name":"Durvalumab","description":"Participants will receive IV durvalumab every 4 weeks.","armGroupLabels":["Cohort A1: ALK-positive (durvalumab arm)","Cohort A2: ROS 1-positive (durvalumab arm)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-free survival (PFS)","timeFrame":"From randomization to the first documented disease progression as determined by blinded independent central review (BICR) per Response Evaluation Criterial in Solid Tumors (RECIST) v1.1, or death from any cause, whichever occurs first (up to 3 years)"}],"secondaryOutcomes":[{"measure":"Time to central nervous system (CNS) progression","timeFrame":"From randomization to the first occurrence of disease progression in the CNS as determined by BICR per RECIST v1.1 (up to 3 years)"},{"measure":"Distant metastasis-free survival (DMFS)","timeFrame":"From randomization to the first occurrence of distant metastasis or death (whichever occurs first) as determined by BICR per RECIST v1.1 (up to 3 years)"},{"measure":"Objective response rate (ORR), defined as the percentage of participants with measurable disease who attain a complete response (CR) or partial response (PR) as determined by the investigator per RECIST v1.1","timeFrame":"Up to 3 years"},{"measure":"PFS","timeFrame":"From randomization to the first documented disease progression as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurs first (up to 3 years)"},{"measure":"Duration of response (DOR)","timeFrame":"From the first documented CR or PR to the first documented disease progression or death (whichever occurs first) as determined by the investigator per RECIST v1.1 (up to 3 years)"},{"measure":"ORR, defined as the percentage of participants with measurable disease who attain a CR or PR as determined by BICR per RECIST v1.1","timeFrame":"Up to 3 years"},{"measure":"DOR","timeFrame":"From the first documented CR or PR to the first documented disease progression or death (whichever occurs first) as determined by BICR per RECIST v1.1 (up to 3 years)"},{"measure":"Overall survival (OS)","timeFrame":"From randomization to death from any cause (up to 5 years)"},{"measure":"Time to CNS progression","timeFrame":"From randomization to the first occurrence of disease progression in the CNS as determined by the investigator per RECIST v1.1 (up to 3 years)"},{"measure":"Time-to-confirmed deterioration (TTCD)","timeFrame":"From randomization to the first deterioration of >/= 10 points that is either maintained for two consecutive assessments or followed by death from any cause within 3 weeks (up to 3 years)"},{"measure":"Proportion of participants who have maintained or improved baseline health as measured by the European Organisation for the Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 physical functioning and role functioning scales","timeFrame":"5, 11, and 17 months"},{"measure":"Proportion of participants who have maintained or improved from their baseline health in cough, chest pain, and dyspnea symptoms as measured using the EORTC QLQ-LC13","timeFrame":"5, 11, and 17 months"},{"measure":"Percentage of participants with adverse events (AEs)","timeFrame":"Up to 3 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria (All Cohorts):\n\n* Body weight \\>/= 30 kg at screening\n* Willingness and ability to use the electronic device(s) or application(s) for the electronic patient-reported outcome (PRO)\n* Whole-body positron emission tomography/computed tomography scan (PET/CT) (from the base of skull to mid-thighs) for the purposes of staging, performed prior and within 42 days for Cohort A2 (ROS1 positive) and 50 days for Cohort A1 (ALK positive) of the first dose of cCRT or sCRT\n* Histologically or cytologically documented locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology\n* Prior receipt of at least two prior cycles of platinum-based chemotherapy given concurrently with radiotherapy (cCRT); or at least two prior cycles of platinum-based chemotherapy given prior to radiotherapy (sCRT)\n* The RT component in the cCRT or sCRT must have been at a total dose of radiation of 60 (+/-10%) Gy (54 Gy to 66 Gy) administered by intensity-modulated radiotherapy (preferred) or three dimension (3D)-conforming technique\n* No disease progression during or following platinum-based cCRT or sCRT\n* Life expectancy \\>/= 12 weeks\n* Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen\n* Tumor PD-L1 status (TC score \\< 1% vs. \\>/= 1% vs. unknown) as determined using the VENTANA PD-L1 IHC SP263 assay (preferred) or the Dako PD-L1 IHC 22C3 pharmDx assay\n* Eastern Cooperative Oncology Group Performance Status of 0, 1, or 2\n* Adequate hematologic and end-organ function\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs, as defined by the protocol\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm, as defined by the protocol\n\nInclusion criteria specific to Cohort A1:\n\n* Documented ALK fusion positivity by an eligible result from: centralized multiplex molecular testing of tumor tissue at the Sponsor's designated central laboratory under Study BX43361 or prior tissue-based testing performed in an accredited or certified laboratory\n\nInclusion criteria specific to Cohort A2:\n\n* Documented ROS1 fusion positivity by an eligible result from: centralized multiplex molecular testing of tumor tissue at the Sponsor's designated central laboratory under Study BX43361 or available results from a Sponsor pre-approved local, appropriately validated ROS1 fusion test on tumor tissue performed in a Clinical Laboratory Improvement Amendments certified or equivalent laboratory\n* Ability to swallow entrectinib intact, without chewing, crushing, or opening the capsules\n\nExclusion Criteria (All Cohorts):\n\n* Any history of previous NSCLC and/or any history of prior treatment for NSCLC (patients must be newly diagnosed with unresectable Stage III disease)\n* Any evidence of Stage IV disease, including, but not limited to, the following: pleural effusion, pericardial effusion, brain metastases, history of intracranial hemorrhage or spinal cord hemorrhage, bone metastases, distant metastases\n* If a pleural effusion is present, the following criteria must be met to exclude malignant involvement (T4 disease): when pleural fluid is visible on both the CT scan and chest X-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative; participants with exudative pleural effusions are excluded regardless of cytology; participants with effusions that are minimal (i.e., not visible on chest X-ray) that are too small to safely tap are eligible\n* NSCLC known to have a known or likely oncogenic-driver mutation in the EGFR gene, as identified by site local testing or Sponsor central testing\n* Liver disease, characterized by any of the following: impaired excretory function (e.g., hyperbilirubinemia), synthetic function, or other conditions of decompensated liver disease, such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices or active viral or active autoimmune, alcoholic, or other types of acute hepatitis\n* Positive hepatitis B surface antigen (HBsAg) test at screening\n* Participants known to be positive for hepatitis C virus (HCV) antibody (Ab) are excluded with the following exception: participants who are HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution are eligible\n* HIV infection: participants are excluded if not well-controlled as defined by the protocol\n* Known active tuberculosis\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the screening chest CT scan\n* Grade \\>/= 2 pneumonitis from prior cCRT or sCRT\n* Any Grade \\> 2 unresolved toxicity from prior cCRT or sCRT\n* Any gastrointestinal (GI) disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post-major bowel resection\n* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications\n* Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions: participants with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study; participants with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study\n* History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\> 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer\n* Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer\n* Major surgical procedure, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study\n* Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin-2) within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during study treatment or within 5 months after the final dose of study treatment\n* Treatment with investigational therapy within 28 days prior to initiation of study treatment\n* Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor-alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with exceptions defined by the protocol\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-cytotoxic T lymphocyte-associated protein 4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies\n* Prior allogeneic stem cell or solid organ transplantation\n* Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study\n* Any condition that, in the opinion of the investigator, would interfere with the evaluation of the study drug or interpretation of patient safety or study results\n* Any prior Grade \\>/= 3 immune-mediated adverse event or any unresolved Grade \\> 1 immune-mediated adverse event while receiving any previous immunotherapy agent other than immune checkpoint blockade agents\n\nExclusion criteria specific to Cohort A1:\n\n* Presence of clinically symptomatic interstitial lung disease or interstitial pneumonitis, including radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention)\n* NSCLC known to have one or more of the following ALK point mutations, as identified by site local testing or Sponsor central testing: I1171X (where X is any other amino acid), V1180L, G1202R\n* Symptomatic bradycardia\n* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina; participants with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction \\< 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate\n* Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia\n* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment\n* Prior treatment with ALK inhibitors\n* History of hypersensitivity to alectinib, durvalumab, or any of their excipients\n* Inability to swallow oral study drug\n* Known hereditary problems of galactose intolerance, a congenital lactase deficiency, or glucose-galactose malabsorption\n* Pregnancy or breastfeeding, or intending to become pregnant during the study treatment or within 90 days after the final dose of alectinib or durvalumab\n\nExclusion criteria specific to Cohort A2:\n\n* Symptomatic bradycardia\n* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina; participants with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction \\< 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate\n* Left ventricular ejection fraction less than or equal to 50% observed during the screening for the study\n* History of prolonged QTc interval (e.g., repeated demonstration of a QTc interval \\> 450 ms from ECGs performed at least 24 hours apart)\n* History of additional risk factors for torsade de pointes (e.g., family history of long QT syndrome)\n* Familial or personal history of congenital bone disorders or bone metabolism alterations\n* Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of the treatment\n* Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia\n* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment\n* Prior treatment with ROS1 inhibitors\n* History of hypersensitivity to entrectinib, durvalumab, and their excipients\n* Grade \\>/= 3 toxicities due to any prior therapy (e.g., RT) (excluding alopecia) that have not shown improvement or are not stable and are considered to interfere with current study drug\n* Known hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption\n* Grade \\>/= 2 peripheral neuropathy\n* Pregnancy or intention of becoming pregnant during study treatment, within 35 days after the final dose of entrectinib, or within 90 days after the final dose of durvalumab","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Reference Study ID Number: BO42777 https://forpatients.roche.com/","role":"CONTACT","phone":"888-662-6728","email":"global-roche-genentech-trials@gene.com"}],"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"University of South Alabama","status":"WITHDRAWN","city":"Mobile","state":"Alabama","zip":"36604","country":"United States","geoPoint":{"lat":30.69436,"lon":-88.04305}},{"facility":"Southern California Kaiser Permanente","status":"WITHDRAWN","city":"Los Angeles","state":"California","zip":"90034","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Rocky Mountain Cancer Centers - Lone Tree","status":"RECRUITING","city":"Lone Tree","state":"Colorado","zip":"80124","country":"United States","geoPoint":{"lat":39.55171,"lon":-104.8863}},{"facility":"Mount Sinai Medical Center","status":"RECRUITING","city":"Miami Beach","state":"Florida","zip":"33140","country":"United States","geoPoint":{"lat":25.79065,"lon":-80.13005}},{"facility":"University Of Michigan","status":"RECRUITING","city":"Ann Arbor","state":"Michigan","zip":"48109-0934","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"Oregon Health Sciences Uni","status":"WITHDRAWN","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Northwest Cancer Specialists, P.C.","status":"RECRUITING","city":"Tigard","state":"Oregon","zip":"97223","country":"United States","geoPoint":{"lat":45.43123,"lon":-122.77149}},{"facility":"Hillman Cancer Center","status":"RECRUITING","city":"Pittsburgh","state":"Pennsylvania","zip":"15232","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Thompson Cancer Survival Center","status":"WITHDRAWN","city":"Knoxville","state":"Tennessee","zip":"37916-2305","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Baptist Cancer Center","status":"WITHDRAWN","city":"Memphis","state":"Tennessee","zip":"38120","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"The University of Texas MD Anderson Cancer Center","status":"RECRUITING","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Mays Cancer Center, UT Health San Antonio","status":"RECRUITING","city":"San Antonio","state":"Texas","zip":"78229-4427","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Virginia Cancer Specialists (Fairfax) - USOR","status":"RECRUITING","city":"Fairfax","state":"Virginia","zip":"22031","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}},{"facility":"Lifehouse","status":"RECRUITING","city":"Camperdown","state":"New South Wales","zip":"2050","country":"Australia","geoPoint":{"lat":-33.88965,"lon":151.17642}},{"facility":"GenesisCare North Shore","status":"WITHDRAWN","city":"St Leonards","state":"New South Wales","zip":"2065","country":"Australia","geoPoint":{"lat":-33.82344,"lon":151.19836}},{"facility":"Westmead Hospital","status":"WITHDRAWN","city":"Westmead","state":"New South Wales","zip":"2145","country":"Australia","geoPoint":{"lat":-33.80383,"lon":150.98768}},{"facility":"Peter MacCallum Cancer Centre","status":"RECRUITING","city":"Melbourne","state":"Victoria","zip":"3000","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"One Clinical Research","status":"RECRUITING","city":"Nedlands","state":"Western Australia","zip":"6009","country":"Australia","geoPoint":{"lat":-31.98184,"lon":115.8073}},{"facility":"GHdC Site Les Viviers","status":"RECRUITING","city":"Charleroi","zip":"6000","country":"Belgium","geoPoint":{"lat":50.41136,"lon":4.44448}},{"facility":"UZ Gent","status":"RECRUITING","city":"Gent","zip":"9000","country":"Belgium","geoPoint":{"lat":51.05,"lon":3.71667}},{"facility":"Hospital Sao Rafael - HSR","status":"WITHDRAWN","city":"Salvador","state":"Bahia","zip":"41253-190","country":"Brazil","geoPoint":{"lat":-12.97111,"lon":-38.51083}},{"facility":"Crio - Centro Regional Integrado de Oncologia","status":"RECRUITING","city":"Fortaleza","state":"Ceará","zip":"60336-550","country":"Brazil","geoPoint":{"lat":-3.71722,"lon":-38.54306}},{"facility":"Instituto do Cancer Brasil","status":"RECRUITING","city":"Tres Lagoas","state":"Mato Grosso Do Sul","zip":"79601-001","country":"Brazil","geoPoint":{"lat":-20.78765,"lon":-51.70338}},{"facility":"Oncocentro Belo Horizonte","status":"RECRUITING","city":"Belo Horizonte","state":"Minas Gerais","zip":"30360-680","country":"Brazil","geoPoint":{"lat":-19.92083,"lon":-43.93778}},{"facility":"COT - Centro Oncologico do Triangulo","status":"RECRUITING","city":"Uberlandia","state":"Minas Gerais","zip":"38408-150","country":"Brazil","geoPoint":{"lat":-18.91861,"lon":-48.27722}},{"facility":"Santa Casa de Misericordia de Porto Alegre","status":"ACTIVE_NOT_RECRUITING","city":"Porto Alegre","state":"Rio Grande Do Sul","zip":"90050-170","country":"Brazil","geoPoint":{"lat":-30.03306,"lon":-51.23}},{"facility":"Hospital Nossa Senhora da Conceicao","status":"RECRUITING","city":"Porto Alegre","state":"Rio Grande Do Sul","zip":"91350-200","country":"Brazil","geoPoint":{"lat":-30.03306,"lon":-51.23}},{"facility":"Clínica de Oncologia Reichow","status":"ACTIVE_NOT_RECRUITING","city":"Blumenau","state":"Santa Catarina","zip":"89010-340","country":"Brazil","geoPoint":{"lat":-26.91944,"lon":-49.06611}},{"facility":"Hospital de Cancer de Barretos","status":"RECRUITING","city":"Barretos","state":"São Paulo","zip":"14784-400","country":"Brazil","geoPoint":{"lat":-20.55722,"lon":-48.56778}},{"facility":"Instituto do Cancer do Estado de Sao Paulo - ICESP","status":"RECRUITING","city":"Sao Paulo","state":"São Paulo","zip":"01246-000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Oncoclinicas Rio de Janeiro S.A.","status":"RECRUITING","city":"Rio de Janeiro","zip":"22250-905","country":"Brazil","geoPoint":{"lat":-22.90278,"lon":-43.2075}},{"facility":"Sunnybrook Health Sciences Centre","status":"RECRUITING","city":"Toronto","state":"Ontario","zip":"M4N 3M5","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}},{"facility":"K2 Oncology","status":"RECRUITING","city":"Providencia","zip":"7500000","country":"Chile","geoPoint":{"lat":-33.43107,"lon":-70.60454}},{"facility":"Centro de Estudios Clínicos SAGA","status":"WITHDRAWN","city":"Santiago","zip":"7500653","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"OrlandiOncología","status":"WITHDRAWN","city":"Santiago","zip":"7500713","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"RedSalud Vitacura","status":"RECRUITING","city":"Santiago","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"James Lind Centro de Investigación Del Cáncer","status":"WITHDRAWN","city":"Temuco","zip":"4800827","country":"Chile","geoPoint":{"lat":-38.73965,"lon":-72.59842}},{"facility":"Beijing Cancer Hospital","status":"WITHDRAWN","city":"Beijing","zip":"100142","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Hunan Cancer Hospital","status":"ACTIVE_NOT_RECRUITING","city":"Changsha City","zip":"410013","country":"China"},{"facility":"Hunan Cancer Hospital","status":"COMPLETED","city":"Changsha City","zip":"410013","country":"China"},{"facility":"Xinqiao Hospital of Third Military Medical University","status":"ACTIVE_NOT_RECRUITING","city":"Chongqing City","zip":"400037","country":"China"},{"facility":"Shandong Cancer Hospital","status":"ACTIVE_NOT_RECRUITING","city":"Jinan","zip":"250117","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School","status":"WITHDRAWN","city":"Nanjing City","zip":"210008","country":"China"},{"facility":"The affiliated hospital of Qingdao university","status":"WITHDRAWN","city":"Qingdao City","zip":"266042","country":"China"},{"facility":"Shanghai Pulmonary Hospital","status":"ACTIVE_NOT_RECRUITING","city":"Shanghai","zip":"200433","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Tianjin Medical University Cancer Institute & Hospital","status":"WITHDRAWN","city":"Tianjing","zip":"300060","country":"China"},{"facility":"Union Hospital Tongji Medical College Huazhong University of Science and Technology","status":"WITHDRAWN","city":"Wuhan City","zip":"430023","country":"China"},{"facility":"Shanxi Cancer Hospital","status":"WITHDRAWN","city":"Xi'an","zip":"030013","country":"China","geoPoint":{"lat":34.25833,"lon":108.92861}},{"facility":"Clinica De La Costa","status":"WITHDRAWN","city":"Barranquilla","zip":"080020","country":"Colombia","geoPoint":{"lat":10.96854,"lon":-74.78132}},{"facility":"Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo","status":"RECRUITING","city":"Bogota, D.C.","zip":"110131","country":"Colombia"},{"facility":"Hospital Universitario San Ignacio","status":"RECRUITING","city":"Bogota","zip":"000472","country":"Colombia","geoPoint":{"lat":4.60971,"lon":-74.08175}},{"facility":"Instituto Cancerología Medellin","status":"RECRUITING","city":"Medellin","zip":"050024","country":"Colombia","geoPoint":{"lat":6.25184,"lon":-75.56359}},{"facility":"Clinica CIMCA","status":"RECRUITING","city":"San Jose","zip":"10103","country":"Costa Rica","geoPoint":{"lat":9.93333,"lon":-84.08333}},{"facility":"ICIMED Instituto de Investigación en Ciencias Médicas","status":"RECRUITING","city":"San José","zip":"10108","country":"Costa Rica","geoPoint":{"lat":9.93333,"lon":-84.08333}},{"facility":"CHU Angers,Service de Pneumologie","status":"RECRUITING","city":"Angers","zip":"49933","country":"France","geoPoint":{"lat":47.46667,"lon":-0.55}},{"facility":"Polyclinique Bordeaux Nord Aquitaine","status":"RECRUITING","city":"Bordeaux","zip":"33300","country":"France","geoPoint":{"lat":44.84044,"lon":-0.5805}},{"facility":"Hôpital Ambroise Paré - Boulogne-Billancourt","status":"RECRUITING","city":"Boulogne Billancourt","zip":"92100","country":"France","geoPoint":{"lat":48.83333,"lon":2.25}},{"facility":"Centre Francois Baclesse","status":"RECRUITING","city":"Caen","zip":"14000","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"facility":"Centre Leon Berard","status":"RECRUITING","city":"Lyon","zip":"69008","country":"France","geoPoint":{"lat":45.74848,"lon":4.84669}},{"facility":"Hopital Nord","status":"RECRUITING","city":"Marseille cedex 20","zip":"13915","country":"France","geoPoint":{"lat":43.29551,"lon":5.38958}},{"facility":"Hôpitaux D'Instruction Des Armees Begin","status":"RECRUITING","city":"St Mande","zip":"94160","country":"France","geoPoint":{"lat":48.83864,"lon":2.41579}},{"facility":"CHU Strasbourg - Nouvel Hopital Civil","status":"RECRUITING","city":"Strasbourg","zip":"67091","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"Hia Sainte Anne","status":"RECRUITING","city":"Toulon","zip":"83041","country":"France","geoPoint":{"lat":43.12442,"lon":5.92836}},{"facility":"CHU de Toulouse - Hôpital Larrey","status":"RECRUITING","city":"Toulouse","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Helios Klinikum Emil von Behring GmbH","status":"RECRUITING","city":"Berlin","zip":"14165","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Klinikum Chemnitz gGmbH","status":"RECRUITING","city":"Chemnitz","zip":"09116","country":"Germany","geoPoint":{"lat":50.8357,"lon":12.92922}},{"facility":"Klinikum Esslingen","status":"RECRUITING","city":"Esslingen","zip":"73730","country":"Germany","geoPoint":{"lat":48.73961,"lon":9.30473}},{"facility":"Thoraxklinik Heidelberg gGmbH","status":"RECRUITING","city":"Heidelberg","zip":"69126","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"LMU Klinikum der Universität München, Medizinische Klinik und Poliklinik V, Campus Innenstadt","status":"RECRUITING","city":"München","zip":"80336","country":"Germany","geoPoint":{"lat":48.13743,"lon":11.57549}},{"facility":"Universitätsklinikum Regensburg","status":"RECRUITING","city":"Regensburg","zip":"93053","country":"Germany","geoPoint":{"lat":49.01513,"lon":12.10161}},{"facility":"Universitätsklinikum Würzburg","status":"RECRUITING","city":"Würzburg","zip":"97078","country":"Germany","geoPoint":{"lat":49.79391,"lon":9.95121}},{"facility":"Queen Mary Hospital","status":"WITHDRAWN","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Rajiv Gandhi Cancer Inst.&Research Center","status":"RECRUITING","city":"New Delhi","state":"Delhi","zip":"110085","country":"India","geoPoint":{"lat":28.63576,"lon":77.22445}},{"facility":"Medanta-The Medicity","status":"RECRUITING","city":"Gurgaon","state":"Haryana","zip":"122001","country":"India","geoPoint":{"lat":28.4601,"lon":77.02635}},{"facility":"Tata Memorial Hospital","status":"RECRUITING","city":"Mumbai","state":"Maharashtra","zip":"400012","country":"India","geoPoint":{"lat":19.07283,"lon":72.88261}},{"facility":"Apollo Gleneagles Hospital","status":"RECRUITING","city":"Kolkata","state":"WEST Bengal","zip":"700054","country":"India","geoPoint":{"lat":22.56263,"lon":88.36304}},{"facility":"Rambam Medical Center","status":"RECRUITING","city":"Haifa","zip":"3109601","country":"Israel","geoPoint":{"lat":32.81841,"lon":34.9885}},{"facility":"Rabin Medical Center-Beilinson Campus","status":"RECRUITING","city":"Petach Tikva","zip":"4941492","country":"Israel","geoPoint":{"lat":32.08707,"lon":34.88747}},{"facility":"IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola","status":"RECRUITING","city":"Meldola","state":"Emilia-Romagna","zip":"47014","country":"Italy","geoPoint":{"lat":44.12775,"lon":12.0626}},{"facility":"IRCCS Istituto Regina Elena (IFO)","status":"RECRUITING","city":"Roma","state":"Lazio","zip":"00144","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Azienda Ospedaliera San Camillo Forlanini","status":"RECRUITING","city":"Roma","state":"Lazio","zip":"00152","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"IRCCS A.O.U San MArtino - IST","status":"RECRUITING","city":"Genova","state":"Liguria","zip":"16132","country":"Italy","geoPoint":{"lat":44.40478,"lon":8.94438}},{"facility":"Asst Degli Spedali Civili Di Brescia","status":"RECRUITING","city":"Brescia","state":"Lombardia","zip":"25123","country":"Italy","geoPoint":{"lat":45.53558,"lon":10.21472}},{"facility":"Irccs Istituto Europeo di Oncologia (IEO)","status":"RECRUITING","city":"Milano","state":"Lombardia","zip":"20141","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"Asst Grande Ospedale Metropolitano Niguarda","status":"RECRUITING","city":"Milano","state":"Lombardia","zip":"20162","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"A.O. Universitaria S. Luigi Gonzaga","status":"RECRUITING","city":"Orbassano","state":"Piemonte","zip":"10043","country":"Italy","geoPoint":{"lat":45.00547,"lon":7.53813}},{"facility":"IRCCS Giovanni Paolo II Istituto Oncologico","status":"RECRUITING","city":"Bari","state":"Puglia","zip":"70124","country":"Italy","geoPoint":{"lat":41.11148,"lon":16.8554}},{"facility":"Azienda Ospedaliero-Universitaria Careggi","status":"RECRUITING","city":"Firenze","state":"Toscana","zip":"50134","country":"Italy","geoPoint":{"lat":43.77925,"lon":11.24626}},{"facility":"IRCCS Istituto Oncologico Veneto (IOV)","status":"RECRUITING","city":"Padova","state":"Veneto","zip":"35128","country":"Italy","geoPoint":{"lat":45.40797,"lon":11.88586}},{"facility":"Ospedale P. Pederzoli Casa di cura Privata","status":"RECRUITING","city":"Peschiera Del Garda (VR)","state":"Veneto","zip":"37019","country":"Italy"},{"facility":"Aichi Cancer Center Hospital","status":"WITHDRAWN","city":"Aichi","zip":"464-8681","country":"Japan","geoPoint":{"lat":32.51879,"lon":130.62158}},{"facility":"Hirosaki University Hospital","status":"WITHDRAWN","city":"Aomori","zip":"036-8563","country":"Japan","geoPoint":{"lat":40.81667,"lon":140.73333}},{"facility":"National Cancer Center East","status":"WITHDRAWN","city":"Chiba","zip":"277-8577","country":"Japan","geoPoint":{"lat":35.6,"lon":140.11667}},{"facility":"Shikoku Cancer Center","status":"WITHDRAWN","city":"Ehime","zip":"791-0280","country":"Japan","geoPoint":{"lat":33.63163,"lon":132.76886}},{"facility":"NHO Kyushu Cancer Center","status":"RECRUITING","city":"Fukuoka","zip":"811-1395","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Kurume University Hospital","status":"RECRUITING","city":"Fukuoka","zip":"830-0011","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Kobe City Medical Center General Hospital","status":"ACTIVE_NOT_RECRUITING","city":"Hyogo","zip":"650-0047","country":"Japan"},{"facility":"National Hospital Organization Himeji Medical Center","status":"WITHDRAWN","city":"Hyogo","zip":"670-8520","country":"Japan"},{"facility":"Kagoshima University Hospital","status":"RECRUITING","city":"Kagoshima","zip":"890-8520","country":"Japan","geoPoint":{"lat":31.56667,"lon":130.55}},{"facility":"Kanagawa Cancer Center","status":"WITHDRAWN","city":"Kanagawa","zip":"241-8515","country":"Japan","geoPoint":{"lat":37.58333,"lon":139.91667}},{"facility":"Kumamoto University Hospital","status":"RECRUITING","city":"Kumamoto","zip":"860-8556","country":"Japan","geoPoint":{"lat":32.80589,"lon":130.69182}},{"facility":"Sendai Kousei Hospital","status":"WITHDRAWN","city":"Miyagi","zip":"980-0873","country":"Japan"},{"facility":"Nara Medical University Hospital","status":"WITHDRAWN","city":"Nara","zip":"634-8522","country":"Japan","geoPoint":{"lat":34.68505,"lon":135.80485}},{"facility":"Niigata Cancer Center Hospital","status":"WITHDRAWN","city":"Niigata","zip":"951-8566","country":"Japan","geoPoint":{"lat":37.88637,"lon":139.00589}},{"facility":"Okayama University Hospital","status":"WITHDRAWN","city":"Okayama","zip":"700-8558","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"Kurashiki Central Hospital","status":"WITHDRAWN","city":"Okayama","zip":"710-8602","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"Kindai University Hospital","status":"RECRUITING","city":"Osaka-sayama","zip":"589-8511","country":"Japan","geoPoint":{"lat":34.69374,"lon":135.50218}},{"facility":"Osaka City General Hospital","status":"WITHDRAWN","city":"Osaka","zip":"534-0021","country":"Japan","geoPoint":{"lat":34.69374,"lon":135.50218}},{"facility":"Osaka International Cancer Institute","status":"WITHDRAWN","city":"Osaka","zip":"541-8567","country":"Japan","geoPoint":{"lat":34.69374,"lon":135.50218}},{"facility":"NHO Kinki Chuo Chest Medical Center","status":"WITHDRAWN","city":"Osaka","zip":"591-8555","country":"Japan","geoPoint":{"lat":34.69374,"lon":135.50218}},{"facility":"Shizuoka Cancer Center","status":"WITHDRAWN","city":"Shizuoka","zip":"411-8777","country":"Japan","geoPoint":{"lat":34.98333,"lon":138.38333}},{"facility":"Juntendo University Hospital","status":"RECRUITING","city":"Tokyo","zip":"113-8431","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Komagome Hospital","status":"WITHDRAWN","city":"Tokyo","zip":"113-8677","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"The Cancer Institute Hospital of JFCR","status":"RECRUITING","city":"Tokyo","zip":"135-8550","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Tottori University Hospital","status":"WITHDRAWN","city":"Tottori","zip":"683-8504","country":"Japan","geoPoint":{"lat":35.5,"lon":134.23333}},{"facility":"National Hospital Organization Yamaguchi - Ube Medical Center","status":"WITHDRAWN","city":"Yamaguchi","zip":"755-0241","country":"Japan","geoPoint":{"lat":34.18333,"lon":131.46667}},{"facility":"Chungbuk National University Hospital","status":"WITHDRAWN","city":"Cheongju-si","zip":"28644","country":"Korea, Republic of","geoPoint":{"lat":36.63722,"lon":127.48972}},{"facility":"Kyungpook National University Chilgok Hospital","status":"RECRUITING","city":"Daegu","zip":"41404","country":"Korea, Republic of","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Pusan National University Yangsan Hospital","status":"RECRUITING","city":"Gyeongsangnam-do","zip":"50612","country":"Korea, Republic of"},{"facility":"Chonnam National University Hwasun Hospital","status":"RECRUITING","city":"Jeollanam-do","zip":"58128","country":"Korea, Republic of"},{"facility":"Seoul National University Bundang Hospital","status":"RECRUITING","city":"Seongnam-si","zip":"13605","country":"Korea, Republic of","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Kangbuk Samsung Hospital","status":"RECRUITING","city":"Seoul","zip":"03181","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Asan Medical Center","status":"RECRUITING","city":"Seoul","zip":"05505","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Korea University Guro Hospital","status":"RECRUITING","city":"Seoul","zip":"08308","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Hospital Civil de Guadalajara Fray Antonio Alcalde","status":"RECRUITING","city":"Guadalajara","state":"Jalisco","zip":"44280","country":"Mexico","geoPoint":{"lat":20.66682,"lon":-103.39182}},{"facility":"Clinstile S.A de C.V.","status":"RECRUITING","city":"Mexico City","state":"Mexico CITY (federal District)","zip":"06700","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Centro de Investigación Oncologica Galerias","status":"RECRUITING","city":"Aguascalientes","zip":"20124","country":"Mexico","geoPoint":{"lat":21.88234,"lon":-102.28259}},{"facility":"ARKE Estudios Clínicos S.A. de C.V.","status":"RECRUITING","city":"Ciudad de México","zip":"06700","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Maastricht University Medical Center","status":"RECRUITING","city":"Maastricht","zip":"6229 HX","country":"Netherlands","geoPoint":{"lat":50.84833,"lon":5.68889}},{"facility":"Auckland City Hospital, Cancer and Blood Research","status":"RECRUITING","city":"Auckland","zip":"1023","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"Oslo university hospital Radiumhospitalet","status":"ACTIVE_NOT_RECRUITING","city":"Oslo","zip":"0424","country":"Norway","geoPoint":{"lat":59.91273,"lon":10.74609}},{"facility":"Instytut Genetyki i Immunologii GENIM","status":"RECRUITING","city":"Lublin","zip":"20-609","country":"Poland","geoPoint":{"lat":51.25,"lon":22.56667}},{"facility":"Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie","status":"RECRUITING","city":"Olsztyn","zip":"10-357","country":"Poland","geoPoint":{"lat":53.77995,"lon":20.49416}},{"facility":"Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu","status":"RECRUITING","city":"Poznan","zip":"60-569","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Dolno?l?skie Centrum Chorób P?uc we Wroc?awiu","status":"RECRUITING","city":"Wroc?aw","zip":"53-439","country":"Poland"},{"facility":"University Clinical Centre of Serbia","status":"RECRUITING","city":"Belgrade","zip":"11030","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Hospital Medical Center Bezanijska kosa","status":"RECRUITING","city":"Belgrade","zip":"11080","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Univ Clinical Center Kragujevac","status":"RECRUITING","city":"Kragujevac","zip":"34000","country":"Serbia","geoPoint":{"lat":44.01667,"lon":20.91667}},{"facility":"Institute for Pulmonary Diseases of Vojvodina","status":"RECRUITING","city":"Sremska Kamenica","zip":"21204","country":"Serbia","geoPoint":{"lat":45.22158,"lon":19.84367}},{"facility":"National Cancer Centre","status":"RECRUITING","city":"Singapore","zip":"168583","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Tan Tock Seng Hospital","status":"RECRUITING","city":"Singapore","zip":"308433","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Complejo Hospitalario Universitario A Coruña (CHUAC)","status":"RECRUITING","city":"A Coruña","state":"LA Coruna","zip":"15006","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Complejo Hospitalario Universitario Insular?Materno Infantil","status":"RECRUITING","city":"Las Palmas de Gran Canaria","state":"LAS Palmas","zip":"35016","country":"Spain","geoPoint":{"lat":28.09973,"lon":-15.41343}},{"facility":"Hospital General Univ. de Alicante","status":"RECRUITING","city":"Alicante","zip":"3010","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"Hospital Universitari Vall d'Hebron","status":"RECRUITING","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Ramon y Cajal","status":"RECRUITING","city":"Madrid","zip":"28034","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario 12 de Octubre","status":"RECRUITING","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario La Paz","status":"RECRUITING","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Regional Universitario Carlos Haya","status":"RECRUITING","city":"Malaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Hospital Universitario Virgen del Rocio","status":"RECRUITING","city":"Sevilla","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Clínico Universitario de Valencia","status":"RECRUITING","city":"Valencia","zip":"46010","country":"Spain","geoPoint":{"lat":39.46975,"lon":-0.37739}},{"facility":"Sahlgrenska University Hospital","status":"RECRUITING","city":"Göteborg","zip":"413 45","country":"Sweden","geoPoint":{"lat":57.70716,"lon":11.96679}},{"facility":"Karolinska Universitetssjukhuset, Solna","status":"RECRUITING","city":"Stockholm","zip":"171 76","country":"Sweden","geoPoint":{"lat":59.33258,"lon":18.0649}},{"facility":"Taipei Medical University ?Shuang Ho Hospital","status":"RECRUITING","city":"New Taipei City","zip":"23561","country":"Taiwan","geoPoint":{"lat":25.01111,"lon":121.44583}},{"facility":"National Cheng Kung Univ Hosp","status":"RECRUITING","city":"Tainan","zip":"00704","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"National Taiwan Uni Hospital","status":"RECRUITING","city":"Taipei City","zip":"10041","country":"Taiwan","geoPoint":{"lat":25.04776,"lon":121.53185}},{"facility":"Taipei Veterans General Hospital","status":"RECRUITING","city":"Taipei City","zip":"112","country":"Taiwan","geoPoint":{"lat":25.04776,"lon":121.53185}},{"facility":"Taipei Medical University Hospital","status":"RECRUITING","city":"Taipei","zip":"110","country":"Taiwan","geoPoint":{"lat":25.04776,"lon":121.53185}},{"facility":"Taipei Municipal Wan Fang Hospital","status":"RECRUITING","city":"Taipei","zip":"119","country":"Taiwan","geoPoint":{"lat":25.04776,"lon":121.53185}},{"facility":"Chang Gung Memorial Hospital - Linkou","status":"RECRUITING","city":"Taoyuan","zip":"333","country":"Taiwan","geoPoint":{"lat":24.95233,"lon":121.20193}},{"facility":"Taichung Veterans General Hospital","status":"ACTIVE_NOT_RECRUITING","city":"Xitun Dist.","zip":"40705","country":"Taiwan"},{"facility":"Rajavithi Hospital","status":"RECRUITING","city":"Bangkok","zip":"10400","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Faculty of Med. Siriraj Hosp.","status":"RECRUITING","city":"Bangkok","zip":"10700","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Oncology Unit, Faculty of Medicine, Vajira Hospital","status":"RECRUITING","city":"Dusit","zip":"10300","country":"Thailand","geoPoint":{"lat":13.7775,"lon":100.51977}},{"facility":"Songklanagarind Hospital","status":"RECRUITING","city":"Songkhla","zip":"90110","country":"Thailand","geoPoint":{"lat":7.19882,"lon":100.5951}},{"facility":"Ataturk Sanatoryum Egitim Ve Arastirma Hastanesi","status":"RECRUITING","city":"Ankara","zip":"06280","country":"Turkey","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Gazi Uni Medical Faculty Hospital","status":"RECRUITING","city":"Ankara","zip":"06500","country":"Turkey","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Liv Hospital Ankara","status":"RECRUITING","city":"Ankara","zip":"06680","country":"Turkey","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji","status":"RECRUITING","city":"Bakirkoy / Istanbul","zip":"34147","country":"Turkey"},{"facility":"Dicle University Faculty of Medicine","status":"RECRUITING","city":"Diyarbakir","zip":"21280","country":"Turkey","geoPoint":{"lat":37.91363,"lon":40.21721}},{"facility":"Ataturk University Medical Faculty Yakutiye Research Hospital Medical Oncology Department","status":"RECRUITING","city":"Erzurum","zip":"25240","country":"Turkey","geoPoint":{"lat":39.90861,"lon":41.27694}},{"facility":"Medipol University Medical Faculty","status":"RECRUITING","city":"Istanbul","zip":"34214","country":"Turkey","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Marmara Uni Faculty of Medicine","status":"WITHDRAWN","city":"Istanbul","zip":"34890","country":"Turkey","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Medikal Park Samsun","status":"RECRUITING","city":"Samsun","zip":"55200","country":"Turkey","geoPoint":{"lat":41.27976,"lon":36.3361}},{"facility":"Medical Park Seyhan Hospital","status":"RECRUITING","city":"Seyhan","zip":"01140","country":"Turkey"},{"facility":"Birmingham Heartlands Hospital","status":"RECRUITING","city":"Birmingham","zip":"B9 5SS","country":"United Kingdom","geoPoint":{"lat":52.48142,"lon":-1.89983}},{"facility":"North Middlesex Hospital","status":"RECRUITING","city":"Harlow","zip":"N18 1QX","country":"United Kingdom","geoPoint":{"lat":51.77655,"lon":0.11158}},{"facility":"Barts & London School of Med","status":"RECRUITING","city":"London","zip":"EC1A 7BE","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Royal Marsden Hospital","status":"RECRUITING","city":"London","zip":"SW3 6JJ","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Christie Hospital Nhs Trust","status":"RECRUITING","city":"Manchester","zip":"M2O 4BX","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-07-07"},"conditionBrowseModule":{"meshes":[{"id":"D008175","term":"Lung Neoplasms"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"}],"browseLeaves":[{"id":"M11172","name":"Lung Neoplasms","asFound":"Lung Cancer","relevance":"HIGH"},{"id":"M5546","name":"Carcinoma, Non-Small-Cell Lung","asFound":"Non-small Cell Lung Cancer","relevance":"HIGH"},{"id":"M5534","name":"Carcinoma","relevance":"LOW"},{"id":"M14979","name":"Respiratory Tract Neoplasms","relevance":"LOW"},{"id":"M16658","name":"Thoracic Neoplasms","relevance":"LOW"},{"id":"M11168","name":"Lung Diseases","relevance":"LOW"},{"id":"M14977","name":"Respiratory Tract Diseases","relevance":"LOW"},{"id":"M5540","name":"Carcinoma, Bronchogenic","relevance":"LOW"},{"id":"M5260","name":"Bronchial Neoplasms","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC08","name":"Respiratory Tract (Lung and Bronchial) Diseases"},{"abbrev":"All","name":"All Conditions"}]},"interventionBrowseModule":{"meshes":[{"id":"C000613593","term":"Durvalumab"},{"id":"C582670","term":"Alectinib"},{"id":"C000607349","term":"Entrectinib"}],"ancestors":[{"id":"D000074322","term":"Antineoplastic Agents, Immunological"},{"id":"D000970","term":"Antineoplastic Agents"},{"id":"D000092004","term":"Tyrosine Kinase Inhibitors"},{"id":"D047428","term":"Protein Kinase Inhibitors"},{"id":"D004791","term":"Enzyme Inhibitors"},{"id":"D045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M272500","name":"Durvalumab","asFound":"Extension","relevance":"HIGH"},{"id":"M145666","name":"Alectinib","asFound":"SABR","relevance":"HIGH"},{"id":"M275492","name":"Entrectinib","asFound":"Masseter","relevance":"HIGH"},{"id":"M1346","name":"Antineoplastic Agents, Immunological","relevance":"LOW"},{"id":"M2889","name":"Tyrosine Kinase Inhibitors","relevance":"LOW"},{"id":"M25820","name":"Protein Kinase Inhibitors","relevance":"LOW"},{"id":"M7951","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"T22","name":"Tyrosine","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}